Current Atherosclerosis Reports

, Volume 9, Issue 5, pp 352–358 | Cite as

Does it matter how you lower blood pressure in patients with uncomplicated hypertension? Weighing the evidence

Article

Abstract

Arterial hypertension is one of the most important preventable causes of death worldwide; therefore, adequate treatment of high blood pressure should be mandatory in each hypertensive patient. Hypertension is now defined on the basis of systolic and diastolic blood pressure levels and classified into stages on the basis of the degree of elevation. Normal blood pressure is widely considered as being less than 120/80 mm Hg. The presence of risk factors such as elevated blood cholesterol, smoking, diabetes, and obesity greatly increases the risk for hypertension-related morbid events. The physiologic link between vascular health and arterial pressure makes it difficult to separate the adverse effects of pressure and vascular functional and structural alterations in determining the adverse complications of hypertension. Several landmark trials in hypertension treatment have been published in the past few years, providing more evidence-based medicine data regarding optimal treatment of hypertension to reduce cardiovascular morbidity and mortality. Maintaining vascular health within the scope of global risk reduction in a personalized manner will be the cornerstone of modern cardiovascular disease prevention rather than waiting until arterial hypertension develops.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Kearney PM, Whelton M, Reynolds K, et al.: Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365:217–223.PubMedGoogle Scholar
  2. 2.
    Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003, 289:2560–2572.Google Scholar
  3. 3.
    1999 World Health Organization-International Society of Hypertension, Guidelines for the management of hypertension: Guidelines Subcommittee. J Hypertens 1999, 17:151–183.Google Scholar
  4. 4.
    Lewington S, Clarke R, Quizilbash N, et al.: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903–1913.PubMedCrossRefGoogle Scholar
  5. 5.
    Vasan RS, Larson MG, Leip EP, et al.: Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001, 345:1291–1297.PubMedCrossRefGoogle Scholar
  6. 6.
    Neaton JD, Wentworth D; Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease (Overall findings and differences by age for 316,099 white men). Arch Intern Med 1992, 152:56–64.PubMedCrossRefGoogle Scholar
  7. 7.
    Kannel WB: Blood pressure as a cardiovascular risk factor. JAMA 1996, 275:1571–1576.PubMedCrossRefGoogle Scholar
  8. 8.
    Lloyd-Jones DM, Dyer AR, Wang R, et al.: Risk factor burden in middle age and lifetime risks for cardiovascular and non-cardiovascular death (Chicago Heart Association Detection Project in Industry. Am J Cardiol 2007, 99:535–540.PubMedCrossRefGoogle Scholar
  9. 9.
    Hsia J, Margolis KL, Eaton CB, et al.; Women’s Health Initiative Investigators. Prehypertension and cardiovascular disease risk in the Women’s Health Initiative. Circulation 2007, 115:855–860.PubMedCrossRefGoogle Scholar
  10. 10.
    Rader DJ: Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med 2007, 120(3 Suppl 1):S12–18.PubMedCrossRefGoogle Scholar
  11. 11.
    Cuspidi C, Meani S, Valerio C, et al.: Age and target organ damage in essential hypertension: role of the metabolic syndrome. Am J Hypertens 2007, 20:296–303.PubMedCrossRefGoogle Scholar
  12. 12.
    Cohn JN: Is it the blood pressure or the blood vessel? J Am Soc Hypertens 2007, 1:5–16.CrossRefGoogle Scholar
  13. 13.
    Hermann M, Flammer A, Luscher TF: Nitric oxide in hypertension. J Clin Hypertens 2006, 8(12 Suppl 4):17–29.CrossRefGoogle Scholar
  14. 14.
    Duprez DA, Cohn JN: Monitoring vascular health beyond blood pressure. Curr Atheroscler Rep 2007, 9:139–144.CrossRefGoogle Scholar
  15. 15.
    Giles TD, Berk BC, Black HR, et al.: Expanding the definition and classification of hypertension. J Clin Hypertens 2005, 7:505–512.CrossRefGoogle Scholar
  16. 16.
    Liao D, Arnett DK, Tyroler HA, et al.: Arterial stiffness and the development of hypertension. The ARIC study. Hypertension 1999, 34:201–206PubMedGoogle Scholar
  17. 17.
    Dernellis J, Panaretou M: Aortic stiffness is an independent predictor of progression to hypertension in nonhypertensive subjects. Hypertension 2005, 45:426–431.PubMedCrossRefGoogle Scholar
  18. 18.
    Cohn JN, Duprez DA, Grandits GA: Arterial elasticity as part of a comprehensive assessment of cardiovascular risk and drug treatment. Hypertension 2005, 46:217–220.PubMedCrossRefGoogle Scholar
  19. 19.
    deSimone G, Devereux RB, Chinali M, et al., for the Strong Heart Study Investigators: Risk factors for arterial hypertension in adults with initial optimal blood pressure. Hypertension 2006, 47:162–167.CrossRefGoogle Scholar
  20. 20.
    Halperin RO, Sesso HD, Ma J, et al.: Dyslipidemia and the risk of incident hypertension in men. Hypertension 2006, 47:45–50.PubMedCrossRefGoogle Scholar
  21. 21.
    Bakx JC, van den Hoogen HJ, van den Bosch WJ, et al.: Development of blood pressure and the incidence of hypertension in men and women over an 18-year period: results of the Nijmegen Cohort Study. J Clin Epidemiol 1999, 52:531–538.PubMedCrossRefGoogle Scholar
  22. 22.
    Lewington S, Clarke R, Quizilbash N, et al.: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903–1913.PubMedCrossRefGoogle Scholar
  23. 23.
    Blood Pressure Lowering Treatment Trialists’ Collaboration: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs. Lancet 2000, 356:1955–1964.CrossRefGoogle Scholar
  24. 24.
    Brown MJ, Palmer CR, Castaigne A, et al.: Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000, 356:366–372.PubMedCrossRefGoogle Scholar
  25. 25.
    Zanchetti A, Bond G, Hennig M, et al.: Calcium antagonist slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine study on atherosclerosis (ELSA), a randomised, double-blind, long-term trial. Circulation 2002, 106:2422–2427.PubMedCrossRefGoogle Scholar
  26. 26.
    Black HR, Elliott WJ, Grandits G, et al.: Principal results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial. JAMA 2003, 289:2073–2082.PubMedCrossRefGoogle Scholar
  27. 27.
    Julius S, Kjelden SE, Weber M, et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022–2031.PubMedCrossRefGoogle Scholar
  28. 28.
    Weber MA, Julius S, Kjeldsen SE, et al.: Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004, 363:2049–2051.PubMedCrossRefGoogle Scholar
  29. 29.
    Dahlof B, Sever PS, Poulter NR, et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895–906.PubMedCrossRefGoogle Scholar
  30. 30.
    Williams B, Lacy PS, Thom SM, et al.: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes. Circulation 2006, 113:1213–1215.PubMedCrossRefGoogle Scholar
  31. 31.
    Julius S, Nesbitt SD, Egan BM, et al.: Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006, 354:1685–1697.PubMedCrossRefGoogle Scholar
  32. 32.
    Schunkert H: Pharmacotherapy for prehypertension—mission accomplished? N Engl J Med 2006, 354:1742–1744.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  1. 1.Cardiovascular Division, VCRC-Room 270University of MinnesotaMinneapolisUSA

Personalised recommendations